title: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
authors.forename: T J
authors.initials: TJ
authors.lastname: O'Rourke
authors.forename: T D
authors.initials: TD
authors.lastname: Brown
authors.forename: K
authors.initials: K
authors.lastname: Havlin
authors.forename: J G
authors.initials: JG
authors.lastname: Kuhn
authors.forename: J B
authors.initials: JB
authors.lastname: Craig
authors.forename: H A
authors.initials: HA
authors.lastname: Burris
authors.forename: W G
authors.initials: WG
authors.lastname: Satterlee
authors.forename: P G
authors.initials: PG
authors.lastname: Tarassoff
authors.forename: D D
authors.initials: DD
authors.lastname: Von Hoff
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine